Suggestions
Anne Horgan (nee Nguyen)
Life Sciences investor
Anne Horgan is a highly educated professional with a strong background in Chemistry.
She holds a Postdoc in Chemistry from Yale University, a Ph.D. in Synthetic Organic Chemistry from the University of Bristol, and a Diplôme d'ingénieur in Chemistry from Institut national des Sciences appliquées de Rouen.
Anne has significant experience in the biotechnology and life sciences sectors, having worked in various roles at reputable organizations such as Advent France Biotechnology, Sofinnova Partners, Cancer Research Technology, Cambridge Biotechnology Ltd, and Yale University.
She has served as a Partner at Advent France Biotechnology and held positions including Senior Associate and Associate in Life Sciences at Sofinnova Partners.
Anne's versatile experience includes roles in business development, project management, and scientific research, with a focus on medicinal chemistry.
Her expertise spans across academia and industry, showcasing her diverse skill set and dedication to the field of Chemistry.
Highlights
Looking forward to the first LifeArc Translational Science Summit! #LATSS2024
Anne Muir Simon Goldman Ekaterina Smirnyagina Chris Baker
Oncology therapeutics is a $185bn market and spend is growing, fuelled by new drug approvals. It is also a field that attracts significant VC investment (growing from $4.4bn in 2017 to $17.6bn in 2021 [source: BIO]). Despite outstanding progress in cancer diagnosis and treatment over the last 25 years, there are still significant areas of unmet medical need and mortality rates remain unacceptably high in certain cancers. Many opportunities exist for the development of better treatments, and we see a shift towards precision medicine – building on the development of targeted cancer therapies which began in the late nineties, it’s now about finding the right treatment for the right patient. In our oncology investments, we look for innovation with a potential for high impact for patients, which can take many forms for example the identification and validation of better targets, the development of new and improved therapeutic modalities, or the combination of several fields to power new high-resolution therapies. We hosted a great session to discuss this in our recent annual investor meeting with excellent presentations from two of our portfolio companies in this area. Mosaic TX, whose vision is to be a world leader in biomarker-specific, targeted oncology therapeutics by reshaping the interface of computational and experimental biology for patients with high unmet needs. Bicycle Therapeutics, whose aim is to become one of the world’s leading solid tumour medicines companies, through the development of precision-guided therapeutics, to penetrate deep into tissues and target intractable cancers. Mathew Garnett Kevin Lee Cambridge Innovation Capital #oncologytherapeutics
